### **FORM PTO-1449**

Att. Docket No. REG 1030A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No.

**REG 1030A** 

Serial No.

to be assigned

Applicant:

Croll-Kalish

Date Filed

Concurrently herewith

For

CIRL3-LIKE PROTEINS, NUCLEIC

ACIDS, AND METHODS OF

MODULATING CIRL3-L-MEDIATED

ACTIVITY

Examiner

Not Yet Known

Anoop Singh

Group Art Unit

Not Yet Known

1632

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **U.S. PATENT DOCUMENTS**

Examiner	Patent	Patent	<u>Name</u>	Class/	Filing
<u>Initials</u>	Number	<u>Date</u>		Subclass	<u>Date</u>
	<del></del>				

## FOREIGN PATENT DOCUMENTS

Examiner <u>Initials</u>	Document <u>Number</u>	<u>Date</u>	Country	Class/ Subclass	Translation <u>Yes</u> <u>No</u>	

**REG 1030A** USSN to be assigned PTO 1449 Form Croll-Kalish et al. Page 2

#### **OTHER DOCUMENTS**

Examine	1
Initials	

Initials	•
	NCBI, AAC77816, Calcium-independent alpha-latrotoxin receptoratus norvegicus], J. Biol. Chem. 274 (9), 5491-5498 (1999).
pp. 2914-2922	Bittner, M.A., et al., The Journal of Neurosciences, Vol. 18, No. 8, (1988).
AS	Krasnoperov, V.G., et al., Neuron, Vol. 18, pp. 925-937.
EXAMINER CONSIDEREI	DATE D

**EXAMINER:** 

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Valeta Gregg Reg. No. 35,127

Attorneys for Applicant Patent Agent for Applicant Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591

(914) 345-7400